Testing effectiveness (Phase 2)Study completedNCT01244451
What this trial is testing
GIMEMA CLL0809 Study (BendOfa)
Who this might be right for
Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; orPatients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines
Gruppo Italiano Malattie EMatologiche dell'Adulto 49